Cullinan Oncology, Inc.

NASDAQ (USD): Cullinan Oncology, Inc. (CGEM)

Last Price


Today's Change

-2.21 (11.61%)

Day's Change

16.78 - 18.92

Trading Volume



Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare


CEO:  Mr. Nadim Ahmed Mr. Nadim Ahmed

Full Time Employees:  85 85

IPO Date:  2021-01-08 2021-01-08

CIK:  0001789972 0001789972

ISIN:  US2300311063 US2300311063

CUSIP:  230031106 230031106

Beta:  -0.06 -0.06

Last Dividend:  0.00 0.00

Dcf Diff:  14.53 14.53

Dcf:  2.28 2.28


Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.


One Main Street,
Cambridge, MA 02142, US

617 410 4650

Be the first to like this. Showing 0 of 0 comments

Post a Comment